← Back to Clinical Trials
Recruiting NCT00001248

NCT00001248 Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT00001248
Status Recruiting
Phase
Sponsor National Institute of Neurological Disorders and Stroke (NINDS)
Condition Multiple Sclerosis
Study Type OBSERVATIONAL
Enrollment 3,750 participants
Start Date 1992-07-23
Primary Completion

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 120 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 3,750 participants in total. It began in 1992-07-23.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Studies performed under 89-N-0045 are designed to examine the natural history of multiple sclerosis (MS) using MRI and immunological measures. In addition to studying the natural history of untreated patients, the natural history of patients receiving approved disease-modifying therapies of MS will be examined. In both cohorts of patients levels of disease activity on MRI will be compared with immunological characteristics in order to help identify disease mechanism. Patients with either definite MS (based either on clinical or combined clinical and MRI criteria) or with an initial presentation of neurological dysfunction consistent with MS will be studied longitudinally by MRI. Disease activity on MRI will be assessed using several MRI measures of disease activity including the number of contrast enhancing lesions, the overall burden of disease, brain atrophy and measures to assess axonal damage. Patients will be assessed clinically and correlations between immunological and genetic factors and disease activity as seen clinically or by MRI will be studied. A second cohort of patients starting the use of approved therapy will also be examined. Patients referred to NIH prior to beginning approved therapy will be assessed with a series of three monthly MRIs to determine the level of pretreatment disease activity. After beginning approved therapy under the direction of their private physician, patients will be followed similarly to the natural history cohort. Immunological and genetic findings will be accessed before and during therapy in order to help establish the mechanisms of action of the therapies and to identify mechanisms accounting for either a response or lack of response to therapy. Part of the collected samples willl be cryopreserved to provide respository for further studies focusing on detection of biomarkers indicative of disease state, disease stage or repsonse to therapies. Additionally, a cohort of normal volunteers will be studied. The studies in the normal volunteers will be used to establish the most appropriate imaging sequences for studying normal white matter in MS patients using magnetization transfer (MT) imaging sequences for studying normal white matter in MS patients using magnetization transfer (MT) imaging and to provide normative immunological measures. ...

Eligibility Criteria

* INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. One of the following: 1. Affected participant with either a diagnosis of MS based on currently accepted diagnostic criteria, or imaging or clinical abnormalities associated with MS. 2. Healthy volunteer. 2. Age \>=18 3. Able to give informed consent. EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation in this study: 1. Contraindication to MRI at the time of initial enrollment (with the exception of pregnancy). 2. Unwilling to allow coded samples to be processed offsite or unwilling to have coded samples used in other studies.

Contact & Investigator

Central Contact

Jenifer E Dwyer

✉ jenifer.dwyer@nih.gov

📞 (301) 496-3825

Principal Investigator

Daniel S Reich, M.D.

PRINCIPAL INVESTIGATOR

National Institute of Neurological Disorders and Stroke (NINDS)

Frequently Asked Questions

Who can join the NCT00001248 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 120 Years, studying Multiple Sclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT00001248 currently recruiting?

Yes, NCT00001248 is actively recruiting participants. Contact the research team at jenifer.dwyer@nih.gov for enrollment information.

Where is the NCT00001248 trial being conducted?

This trial is being conducted at Bethesda, United States.

Who is sponsoring the NCT00001248 clinical trial?

NCT00001248 is sponsored by National Institute of Neurological Disorders and Stroke (NINDS). The principal investigator is Daniel S Reich, M.D. at National Institute of Neurological Disorders and Stroke (NINDS). The trial plans to enroll 3,750 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology